Search

Displaying results 4081 - 4090 of 5261 in total
  1. Drug

    Ketobemidone

    go.drugbank.com/drugs/DB06738
    Investigational

    The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection.

  2. Drug

    3-Acetylpyridine Adenine Dinucleotide

    go.drugbank.com/drugs/DB03363
    Experimental

    A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. … It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)

  3. Drug

    Piperidione

    go.drugbank.com/drugs/DB13224
    Experimental

    Piperidione was cough medicine marketed by Roche under the trade name Sedulon.

  4. Drug

    Nocodazole

    go.drugbank.com/drugs/DB08313
    Experimental

    Nocodazole is an antineoplastic agent which exerts its effect by depolymerizing microtubules.

  5. Drug

    BCL-005

    go.drugbank.com/drugs/DB17242
    Experimental

    BCL-005 is a product formed by fused (hybrid) melanoma-dendritic cells.

  6. Drug

    Levobunolol

    go.drugbank.com/drugs/DB01210
    Approved

    A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.

  7. Drug

    IMM101

    go.drugbank.com/drugs/DB15851
    Experimental

    1500 participants to evaluate the vaccine’s protective effects on cancer patients from severe COVID-19 infection (NCT04442048). … As of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over

  8. Drug

    TL-895

    go.drugbank.com/drugs/DB16471
    Investigational

    TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively.

  9. Drug

    Maropitant

    go.drugbank.com/drugs/DB11427
    ExperimentalVet approved

    It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats. … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.

  10. Drug

    Human ciliary neurotrophic factor, recombinant (E. coli)

    go.drugbank.com/drugs/DB17959
    Experimental

    The trials were NCT03071965, an extension study of the NT-501 CNTF implant for macular telangiectasia, and NCT01949324, a Phase 2 multicenter randomized clinical trial of CNTF for macular telangiectasia